Genome Engineering @CRISPR-Tech
Turn on notifications
Flag as spam
Dear Investors, Here is your monthly update for July 2018 The CRISPR-Tech CopyFund is a thematic investment portfolio, which means its strategy is based on a particular investment theme, in this case selecting bio-tech or pharmateutical stocks focusing on CRISPR-Technology. This CopyFund’s portfolio is built by eToro’s investment committee. The <a href="/markets/spx500" class="e-link">$SPX500</a> is currently up 6.5% this year. This CopyFund’s portfolio is currently up 2.3%, no longer outperforming the index. This month was a flat month for the CopyFund closing in a loss of 0.5%. This CopyFund is a long-term investment vehicle. Therefore, since market trends can change over time, you should set realistic goals and assess your investment performance over a prolonged period. The risk remained the same for this CopyFund over the last month. You can read about CRISPR technology and its growth potential here: <a href="" class="e-link" target="_blank" rel="noopener noreferrer"></a> As this is as a relatively emerging market and some of the stocks have a smaller market cap compared to others, increaed volatility in this portfolio is possible. Increased risk, can mean larger swings both ways in terms of profit and loss. Please bear this in mind. If you are planning to add funds to your existing investment, you can do so by closing your current investment and reopen it with your desired investment amount. Please remember past performance is not indicative of any future performance. <a href="/markets/ntla" class="e-link">$NTLA (Intellia Therapeutics Inc)</a>, <a href="/markets/mrk" class="e-link">$MRK (Merck)</a>, <a href="/markets/clls" class="e-link">$CLLS (Cellectis SA)</a>, <a href="/markets/edit" class="e-link">$EDIT (Editas Medicine Inc)</a>, <a href="/markets/a" class="e-link">$A (Agilent Technologies Inc)</a>, <a href="/markets/sgmo" class="e-link">$SGMO (Sangamo Biosciences Inc)</a>, <a href="/markets/regn" class="e-link">$REGN (Regeneron Pharmaceuticals)</a> " ... Show More